Sifting through countless of stocks in the Pharmaceuticals industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Bayer Aktiengesellschaft, Bayer Aktiengesellschaft or Bristol-Myers Squibb Company because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Bayer Aktiengesellschaft, Bayer Aktiengesellschaft and Bristol-Myers Squibb Company compare based on key financial metrics to determine which better meets your investment needs.

About Bayer Aktiengesellschaft, Bayer Aktiengesellschaft and Bristol-Myers Squibb Company

Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment offers nonprescription over-the-counter medicines for self-medication and self-care; nutritional supplements; allergy, cough, and cold; dermatology; pain and cardiovascular risk prevention; and digestive health products. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solutions, and pest and weed management products, as well as customer services for agriculture. It also engages in the breeding, propagation, and production/processing of seeds, including seed dressing. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft has a strategic alliance with The University of Colorado Anschutz, along with UCHealth and Children's Hospital Colorado to advance drug development and clinical trials. Bayer Aktiengesellschaft has a strategic alliance Henry Ford Health. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.

Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment offers nonprescription over-the-counter medicines for self-medication and self-care; nutritional supplements; allergy, cough, and cold; dermatology; pain and cardiovascular risk prevention; and digestive health products. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solutions, and pest and weed management products, as well as customer services for agriculture. It also engages in the breeding, propagation, and production/processing of seeds, including seed dressing. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft has a strategic alliance with The University of Colorado Anschutz, along with UCHealth and Children's Hospital Colorado to advance drug development and clinical trials. Bayer Aktiengesellschaft has a strategic alliance Henry Ford Health. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.

Latest Pharmaceuticals and Bayer Aktiengesellschaft, Bayer Aktiengesellschaft Stock News

As of September 1, 2026, Bayer Aktiengesellschaft had a $55.7 billion market capitalization, compared to the Pharmaceuticals median of $654.2 million. Bayer Aktiengesellschaft’s stock is up 31.4% in 2026, down 0.2% in the previous five trading days and up 71.78% in the past year.

Currently, Bayer Aktiengesellschaft does not have a price-earnings ratio. Bayer Aktiengesellschaft’s trailing 12-month revenue is $51.8 billion with a -3.8% net profit margin. As of September 1, 2026, Bayer Aktiengesellschaft has not reported significant year-over-year quarterly sales. Analysts expect adjusted earnings to reach $1.297 per share for the current fiscal year. Bayer Aktiengesellschaft does not currently pay a dividend.

As of September 1, 2026, Bayer Aktiengesellschaft had a $55.7 billion market cap, putting it in the 94th percentile of all stocks. Bayer Aktiengesellschaft’s stock is up 31.4% in 2026, down 0.2% in the previous five trading days and up 71.78% in the past year.

Currently, Bayer Aktiengesellschaft does not have a price-earnings ratio. Bayer Aktiengesellschaft’s trailing 12-month revenue is $51.8 billion with a -3.8% net profit margin. As of September 1, 2026, Bayer Aktiengesellschaft has not reported significant year-over-year quarterly sales. Analysts expect adjusted earnings to reach $1.297 per share for the current fiscal year. Bayer Aktiengesellschaft does not currently pay a dividend.

How We Compare Bayer Aktiengesellschaft, Bayer Aktiengesellschaft and Bristol-Myers Squibb Company Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Bayer Aktiengesellschaft, Bayer Aktiengesellschaft and Bristol-Myers Squibb Company’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Bayer Aktiengesellschaft, Bayer Aktiengesellschaft and Bristol-Myers Squibb Company Stock Value Grades

Company	Ticker	Value
Bayer Aktiengesellschaft	BAYRY	na
Bayer Aktiengesellschaft	BAYRY	na
Bristol-Myers Squibb Company	BMY	C

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Bayer Aktiengesellschaft does not have a meaningful Value Score. Bayer Aktiengesellschaft does not have a meaningful Value Score. Bristol-Myers Squibb Company has a Value Score of 52, which is Average.

The Value Stock Winner: No Clear Winner

Neither Bayer Aktiengesellschaft, Bayer Aktiengesellschaft or Bristol-Myers Squibb Company has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Bayer Aktiengesellschaft, Bayer Aktiengesellschaft or Bristol-Myers Squibb Company is the better investment when it comes to value.

Bayer Aktiengesellschaft, Bayer Aktiengesellschaft and Bristol-Myers Squibb Company’s Quality Grades

Company	Ticker	Quality
Bayer Aktiengesellschaft	BAYRY	B
Bayer Aktiengesellschaft	BAYRY	B
Bristol-Myers Squibb Company	BMY	A

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Bayer Aktiengesellschaft has a Quality Score of 73, which is Strong. Bayer Aktiengesellschaft has a Quality Score of 73, which is Strong. Bristol-Myers Squibb Company has a Quality Score of 96, which is Very Strong.

The Quality Grade Winner: It’s a Tie!

Looking at the Quality Grade breakdown above, both Bayer Aktiengesellschaft, Bayer Aktiengesellschaft and Bristol-Myers Squibb Company have a grade of B. For investors who focus solely on a company’s overall quality, you will need to conduct further research into both companies to see if they are a good fit for your portfolio. As a good rule of thumb, you should always analyze multiple factors based on a wide range of metrics before choosing a company to invest in.

Bayer Aktiengesellschaft, Bayer Aktiengesellschaft and Bristol-Myers Squibb Company’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Bayer Aktiengesellschaft	BAYRY	F
Bayer Aktiengesellschaft	BAYRY	F
Bristol-Myers Squibb Company	BMY	B

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Bayer Aktiengesellschaft has a Earnings Estimate Score of 5, which is Very Negative. Bayer Aktiengesellschaft has a Earnings Estimate Score of 5, which is Very Negative. Bristol-Myers Squibb Company has a Earnings Estimate Score of 77, which is Positive.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither Bayer Aktiengesellschaft, Bayer Aktiengesellschaft or Bristol-Myers Squibb Company has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Bayer Aktiengesellschaft, Bayer Aktiengesellschaft or Bristol-Myers Squibb Company is the better investment when it comes to estimate revisions.

Other Bayer Aktiengesellschaft, Bayer Aktiengesellschaft and Bristol-Myers Squibb Company Grades

In addition to Value, Estimate Revisions and Quality, A+ Investor also provides grades for Growth and Momentum.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Bayer Aktiengesellschaft, Bayer Aktiengesellschaft and Bristol-Myers Squibb Company pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Bayer Aktiengesellschaft, Bayer Aktiengesellschaft or Bristol-Myers Squibb Company Stock?

Overall, Bayer Aktiengesellschaft stock has a Value Score of , Estimate Revisions Score of 5 and Quality Score of 73.

Bayer Aktiengesellschaft stock has a Value Score of , Estimate Revisions Score of 5 and Quality Score of 73.

Bristol-Myers Squibb Company stock has a Value Score of 52, Estimate Revisions Score of 77 and Quality Score of 96.

Comparing Bayer Aktiengesellschaft, Bayer Aktiengesellschaft and Bristol-Myers Squibb Company’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.